Patient-tailored therapy in haemophilia A: Towards pharmacokinetically guided dosing of factor VIII replacement therapy

In Special Issue 5 of 2015 (1) I. van Moort, (2) R. A. A. Mathôt and (1) M. H. Cnossen (1Department of Pediatric Hematology, Sophia Children’s Hospital, Erasmus University Medical Center, The Netherlands. 2 Department of Clinical Pharmacy, Academic Medical Center, The Netherlands) described the patient-tailored therapy in haemophilia A: Towards pharmacokinetically guided dosing of factor VIII replacement therapy.

Related items

Analytical Information : 6

Cases : 4

Guidelines : 1

Haemostatic Cascade : 6

Quality Issues : 3

Analytical Information

Assays

Cases

ECAT Documentation

Guidelines

Haemostatic Cascade

Parameter

Quality Issues

Surveys and Studies

Terminology

Patient-tailored therapy in haemophilia A: Towards pharmacokinetically guided dosing of factor VIII replacement therapy

Related items

Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays

The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies

Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors

The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop

Analytical performance specifications for hemostasis parameters

The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys

Haemophilia A and treatment, case study

A severe haemophilia A patient treated with emicizumab, case study

Acquired haemophilia A

Acquired Hemophilia A, case study

Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations

TF Pathway (Extrinsic) with Common Pathway (PT)

Intrinsic Pathway APTT

Coagulation Pathways (All Components)

Activation of TAFI by Thrombin

Activation of Protein C by Thrombin

Activation of Platelets by Thrombin

Quality Assurance of replacement therapy and future perspectives

External quality assessment for Factor VIII and Factor IX

The between-laboratoy variation of Factor VIII inhibitor testing

Clotpedia

© 2022 ECAT Clotpedia All Rights Reserved

ECAT Foundation
P.O. Box 107
2250 AC Voorschoten | The Netherlands
Email: info@ecat.nl
T: +31 (0) 71 3030 910 | F: +31 (0) 71 3030 919

Clotpedia Support Form

Success

Patient-tailored therapy in haemophilia A: Towards pharmacokinetically guided dosing of factor VIII replacement therapy

Related items

ECAT Foundation P.O. Box 107 2250 AC Voorschoten | The Netherlands Email: info@ecat.nl T: +31 (0) 71 3030 910 | F: +31 (0) 71 3030 919

ECAT Foundation
P.O. Box 107
2250 AC Voorschoten | The Netherlands
Email: info@ecat.nl
T: +31 (0) 71 3030 910 | F: +31 (0) 71 3030 919